Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Curr Drug Targets ; 21(16): 1672-1686, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32753007

RESUMEN

Female genital tract infections have a high incidence among different age groups and represent an important impact on public health. Among them, vaginitis refers to inflammation of the vulva and/or vagina due to the presence of pathogens that cause trichomoniasis, bacterial vaginosis, and vulvovaginal candidiasis. Several discomforts are associated with these infections, as well as pregnancy complications and the facilitation of HIV transmission and acquisition. The increasing resistance of microorganisms to drugs used in therapy is remarkable, since women report the recurrence of these infections and associated comorbidities. Different resistant mechanisms already described for the drugs used in the therapy against Trichomonas vaginalis, Candida spp., and Gardnerella vaginalis, as well as aspects related to pathogenesis and treatment, are discussed in this review. This study aims to contribute to drug design, avoiding therapy ineffectiveness due to drug resistance. Effective alternative therapies to treat vaginitis will reduce the recurrence of infections and, consequently, the high costs generated in the health system, improving women's well-being.


Asunto(s)
Farmacorresistencia Microbiana/fisiología , Vaginitis/tratamiento farmacológico , Animales , Antiinfecciosos/farmacología , Antiinfecciosos/uso terapéutico , Candidiasis Vulvovaginal/tratamiento farmacológico , Candidiasis Vulvovaginal/microbiología , Femenino , Humanos , Tricomoniasis/tratamiento farmacológico , Tricomoniasis/microbiología , Trichomonas vaginalis/efectos de los fármacos , Trichomonas vaginalis/microbiología , Vaginitis/microbiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA